Close Menu

NEW YORK – Genentech announced on Tuesday that its immunotherapy atezolizumab (Tecentriq) was approved by the US Food and Drug Administration as a first-line option for adult patients with metastatic non-squamous non-small cell lung cancer who don't harbor EGFR or ALK genomic tumor aberrations. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.